{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T18:24:04Z","timestamp":1700072644577},"reference-count":0,"publisher":"Oxford University Press (OUP)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,6,15]]},"DOI":"10.1093\/ajhp\/59.12.1173","type":"journal-article","created":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T22:21:22Z","timestamp":1550874082000},"page":"1173-1179","source":"Crossref","is-referenced-by-count":9,"title":["Managing hyperlipidemia: Current and future roles of HMG-CoA reductase inhibitors"],"prefix":"10.1093","volume":"59","author":[{"given":"Larry M.","family":"Lopez","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, University of Florida, Gainesville, FL 32610"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/59\/12\/1173\/28437438\/ajhp1173.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T17:21:55Z","timestamp":1555348915000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/59\/12\/1173\/5155811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6,15]]},"references-count":0,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2002,6,15]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/59.12.1173","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2002,6,15]]},"published":{"date-parts":[[2002,6,15]]}}}